Abstract
The inflammatory myopathies consist of three distinct groups: dermatomyositis, polymyositis, and inclusion body myositis. Dermatomyositis is distinguished by its characteristic rash, while polymyositis is a diagnosis of exclusion. Inclusion body myositis is characterized by early involvement of distal muscle groups and the quadriceps. Definitive diagnosis is made by muscle biopsy, which demonstrates histological features characteristic for each disorder. Immune mechanisms play a role in the pathogenesis of the inflammatory myopathies. A complement-mediated microangiopathy is seen in dermatomyositis, while there is evidence for a T cell-mediated process in polymyositis and inclusion body myositis. Treatment with prednisone is helpful to a majority of patients for a period of time. Immunosuppressive drugs have met with limited success. We describe a group of patients with dermatomyositis, resistant to available therapies, whose muscle strength, skin changes, and muscle biopsies improved significantly during treatment with intravenous immune globulin. The treatment of polymyositis and inclusion body myositis with intravenous immune globulin is currently under study.
Similar content being viewed by others
References
Dalakas MC: Polymyositis, dermatomyositis, and inclusion-body myositis. N Engl J Med 325:1487–1498, 1991
Dalakas MC: Inflammatory myopathies: Pathogenesis and treatment. Neuropharmacology 5:327–351, 1992
Dalakas MC (ed): Polymyositis and Dermatomyositis. Boston, Butterworths, 1988
Engel AG, Hanhfeld R, Banker BQ: The polymyositis and dermatomyositis syndrome.In Myology, Engel AG, Franzini-Armstrong C (eds). New York, McGraw-Hill, 1994, pp 1335–1383
Rowland LP: Dermatomyositis and polymyositis.In Merritt's Textbook of Neurology, Rowland LP (ed). Philadelphia, Lea & Febiger, 1984, pp 592A-592F
Whitaker JN: Inflammatory myopathy: A review of etiologic and pathogenetic factors. Muscle Nerve 5:573–592, 1982
Dalakas MC: Inflammatory myopathies. Curr Opin Neurol Neurosurg 3:689–696, 1990
Plotz PH, Dalakas MC, Leff RL, Love LA, Miller FW, Cronin ME: Current concepts in the idiopathic inflammatory myopathies: Polymyositis, dermatomyositis and related disorders. Ann Intern Med 111:143–157, 1989
Karpati G, Carpenter S: Idiopathic inflammatory myopathies. Curr Opin Neurol Neurosurg 1:806–814, 1988
Engel AG, Emslie-Smith AM: Inflammatory myopathies. Curr Opin Neurol Neurosurg 2:695–700, 1989
Walton J: The idiopathic inflammatory myopathies and their treatment. J Neurol Neurosurg Psychiat 54:285–287, 1991
Kissel JT, Mendell JR, Rammohan KW: Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med 314:329–334, 1986
Emslie-Smith AM, Engel AG: Microvascular changes in early and advanced dermatomyositis: A quantitative study. Ann Neurol 27:343–356, 1990
Engel AG, Arahata K: Mononuclear cells in myopathies: Quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies. Hum Pathol 17:704–721, 1986
Emslie-Smith AM, Arahata K, Engel AG: Major histocompatibility complex class-1 antigen expression, immuno-localization of interferon subtypes and T-cell-mediated cytotoxicity in myopathies. Hum Pathol 29:224–231, 1989
Karpati G, Pouliot Y, Carpenter S: Expression of immunoreactive major histocapability complex products in human skeletal muscles. Ann Neurol 23:64–72, 1988
Hanhfeld R, Engel AG: Co-culture with autologous myotubes of cytotoxic T cells isolated from muscle in inflammatory myopathies. Ann Neurol 29:498–507, 1991
Dalakas MC: Treatment of polymyositis and dermatomyositis with corticosteroids: A first therapeutic approach.In Polymyositis and Dermatomyositis, Dalakas MC (ed). Boston, Butterworths, 1988, pp 235–253
Dalakas MC: Treatment of polymyositis and dermatomyositis. Curr Opin Rheumatol 1:443–449, 1989
Jan S, Beretta S, Maggio M, Alobbati L, Pellegrini G: High-dose intravenous human immunoglobulin in polymyositis resistant to therapy. J Neurol Neurosurg Psychiat 55:60–64, 1992
Cherin P, Herson S, Wechsler B: Efficacy of intravenous immunoglobulin therapy in chronic refractory polymyositis and dermatomyositis: An open study with 90 adult patients. Am J Med 91:162–168, 1991
Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, Dinsmore ST, McCrosky S: A controlled trial of high-dose intravenous immunoglobulin infusions as treatment for dermatomyositis. N Engl J Med 329:1993–2000, 1993
Basta M, Dalakas MC: High dose intravenous immune globulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 94(4):1729–1735, 1994
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dalakas, M.C. Update on the use of intravenous immune globulin in the treatment of patients with inflammatory muscle disease. J Clin Immunol 15 (Suppl 6), S70–S75 (1995). https://doi.org/10.1007/BF01540896
Issue Date:
DOI: https://doi.org/10.1007/BF01540896